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Background: Autism spectrum disorders (ASDs) comprise a range of neurodevelopmental conditions of varying
severity, characterized by marked qualitative difficulties in social relatedness, communication, and behavior. Despite
overwhelming evidence of high heritability, results from genetic studies to date show that ASD etiology is
extremely heterogeneous and only a fraction of autism genes have been discovered.
Methods: To help unravel this genetic complexity, we performed whole exome sequencing on 100 ASD individuals
from 40 families with multiple distantly related affected individuals. All families contained a minimum of one pair of
ASD cousins. Each individual was captured with the Agilent SureSelect Human All Exon kit, sequenced on the
Illumina Hiseq 2000, and the resulting data processed and annotated with Burrows-Wheeler Aligner (BWA), Genome
Analysis Toolkit (GATK), and SeattleSeq. Genotyping information on each family was utilized in order to determine
genomic regions that were identical by descent (IBD). Variants identified by exome sequencing which occurred in
IBD regions and present in all affected individuals within each family were then evaluated to determine which may
potentially be disease related. Nucleotide alterations that were novel and rare (minor allele frequency, MAF, less
than 0.05) and predicted to be detrimental, either by altering amino acids or splicing patterns, were prioritized.
Results: We identified numerous potentially damaging, ASD associated risk variants in genes previously unrelated
to autism. A subset of these genes has been implicated in other neurobehavioral disorders including depression
(SLIT3), epilepsy (CLCN2, PRICKLE1), intellectual disability (AP4M1), schizophrenia (WDR60), and Tourette syndrome
(OFCC1). Additional alterations were found in previously reported autism candidate genes, including three genes
with alterations in multiple families (CEP290, CSMD1, FAT1, and STXBP5). Compiling a list of ASD candidate genes
from the literature, we determined that variants occurred in ASD candidate genes 1.65 times more frequently than
in random genes captured by exome sequencing (P = 8.55 × 10-5).
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Conclusions: By studying these unique pedigrees, we have identified novel DNA variations related to ASD,
demonstrated that exome sequencing in extended families is a powerful tool for ASD candidate gene discovery,
and provided further evidence of an underlying genetic component to a wide range of neurodevelopmental and
neuropsychiatric diseases.
Keywords: Autism spectrum disorder (ASD), Identical by descent (IBD), Single nucleotide variant (SNV), Whole
exome sequencingBackground
Autism spectrum disorders (ASDs) encompass a constel-
lation of neurodevelopmental conditions characterized
by three features: marked qualitative difficulties in social
relatedness, communication, and behavior [1]. ASDs occur
in approximately one of every 88 individuals and genetic
studies to date demonstrate that the ASD etiology is highly
complex with over 100 candidate genes being implicated in
ASD etiology through linkage, association, and candidate
gene studies [2,3]. This genetic complexity is compounded
by the fact that many families present with private and rare
alterations and that known pathogenic alterations can result
in a variety of clinical consequences [4-6]. Indeed, genetic
overlap has been reported between ASDs and other neuro-
developmental and neuropsychiatric disorders including
attention deficit hyperactivity disorder (ADHD), intellectual
disability, schizophrenia, and Tourette syndrome [7-11].
With the advent of whole exome sequencing, studies
have been rapidly identifying rare genetic variants and
pinpointing the causes of classic Mendelian disorders
[12]. However, exome sequencing of more complex disor-
ders, such as autism, have primarily focused either on
simplex families to discover de novo alterations [13-17]
or consanguineous families that carry recessive mutations
[18,19]. In contrast, we designed a study to perform whole
exome sequencing in extended, multiplex families with at
least an affected cousin pair to identify potential new ASD
loci. We hypothesized that identical by descent (IBD) fil-
tering in these pedigrees would permit us to isolate genes
contributing to ASD pathogenesis since these extended
families are likely to carry novel ASD susceptibility loci of
moderate to high effect. Our strategy discovered potentially
damaging alterations in both known and novel ASD
candidate genes, as well as in genes that carry variations
known to be pathogenic in other neurological disorders.Methods
Ethics statement
We ascertained individuals at the John P. Hussman Insti-
tute for Human Genomics (HIHG) at the University of
Miami, Miller School of Medicine (Miami, FL, USA), the
University of South Carolina (Columbia, SC, USA), and the
Center for Human Genetics Research at Vanderbilt Univer-
sity (Nashville, TN, USA). Written informed consent wasobtained from parents for all minor children and those
who were unable to give consent. In addition, we obtained
assent from all participants of the appropriate develop-
mental and chronological age. All participants were ascer-
tained using the protocol approved by the appropriate
Institutional Review Boards. Patients were collected for this
study for over a decade, with protocols and amendments
being approved at each stage. Oversight of the study falls
under the University of Miami (UM) Institutional Review
Board (IRB). This study was approved by the UM Medical
Sciences IRB Committee B members: Ofelia Alvarez MD,
Abdul Mian PhD, Jose Castro MD, Rabbi Hector Epelbaum
MA, Jean Jose DO, Howard Landy MD, Bruce Nolan
MD FACP FAASM, Eric Zetka PharmD, and Liza Gordillo
BA BS.Sample selection
One hundred and sixty-four individuals (100 ASD patients:
90 males and 10 females; 5 relatives with ASD features: 2
males and 3 females; and 59 unaffected relatives: 27 males
and 32 females) from 40 ASD extended families were used
in this study [Additional file 1: Table S1]. We define
extended families as multiplex families with at least
one pair of ASD affected cousins. Each family has between
two to five ASD individuals and relationships to each other
range from first degree relatives (that is, parent–child and
siblings) to distant relatives (that is, third cousins). Thirty-
nine families were of European ancestry, while a single
family (7606) was of African ancestry. All participants
were enrolled using protocols approved by the appropriate
Institutional Review Boards. Core inclusion criteria for
ASD individuals included: (1) between 3 and 21 years of
age, (2) a presumptive clinical diagnosis of ASD, (3) an
expert clinical determination of an ASD diagnosis using
DSM-IV criteria [1] supported by the Autism Diagnostic
Interview-Revised (ADI-R) [20], and (4) an IQ equiva-
lent >35 or developmental level >18 months as determined
by the Vineland Adaptive Behavior Scale (VABS) [21].
Diagnostic determination was based on review by a panel
consisting of experienced clinical psychologists and a
pediatric medical geneticist. In those instances where
an ADI-R was not available, a best-estimate diagnosis
was assigned using all available clinical information includ-
ing clinician summaries, a caregiver report, and medical
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from administration of any of several measures (for ex-
ample, age appropriate Wechsler scale, Leiter intelligence
test, or Mullen Scales of Early Learning, MSEL) or from
medical records. A summary of the sample is provided in
Additional file 1: Table S2. DNA was isolated either from
saliva (n = 2) or whole blood collected via venipuncture
(n = 162).
Whole exome sequencing and variant detection
One hundred and sixty-four samples from extended ASD
families were prepared following standard Agilent (Santa
Clara, CA, USA) and Illumina (San Diego, CA, USA) pro-
tocols for whole exome sequencing (Figure 1). Briefly, 3 μg
of genomic DNA was sheared to approximately 150 to 200
base pair fragments with the Covaris (Woburn, MA, USA)
E210 and sequence capture performed with Agilent’s Sure-
Select Human All Exon kit. Samples were hybridized for 24
hours. The initial 19 samples were prepared with the 38
Mb kit and run on Illumina’s Genome Analyzer IIx with
each individual being run in two lanes. The remaining 145
samples were captured using the 50 Mb kit, indexed, and
multiplexed to run three per lane on the Illumina Hiseq
2000. Paired end 2 × 100 sequencing was performed.Figure 1 Flowchart of sequencing and filtering methods to identify a
as well as two genotyping platforms, whole genome SNP array and exome
array genotyping calls were compared to variants identified by exome seq
exome sequencing were made either by genotyping on the HumanExome
by descent.Sequencing data was processed using the Illumina Real
Time Analysis (RTA) base calling pipeline, initially with
version 1.7 and with a subset being run on version 1.8.
Alignment to the hg19 human reference genome was
executed with the Burrows-Wheeler Aligner (BWA) and
variant calling performed with the Genome Analysis Tool-
kit (GATK) [22,23]. GATK parameters included base qual-
ity score recalibration and duplicate removal [24]. Samples
captured by the 38 Mb kit had an average depth of 64.4x,
while the remaining samples processed with the 50 Mb kit
had an average depth of 55.78x (Table 1). Variants were
called at positions with a VQSLOD score greater than
zero and minimum read depth of 4x. Alterations were
annotated utilizing the SeattleSeq [25], PolyPhen-2 [26],
and Sorting Intolerant From Tolerant (SIFT) programs [27].
The SeattleSeq program categorizes the two nucleotides
flanking each exon as positions which, when altered, could
potentially result in splicing alterations. In addition to
samples from the autism extended families, 308 unrelated
individuals of European ancestry negative for autism were
internally processed at the HIHG. These HIHG control
samples were captured with the Agilent SureSelect Hu-
man All Exon 50 Mb kit and processed according to the
pipeline described above. Figure 1 outlines the steps usednd prioritize IBD variants. The data from whole exome sequencing
chip array, were each independently generated and processed. SNP
uencing as a quality check. Independent confirmation of calls from
BeadChip or by traditional Sanger sequencing. IBD, identical






1x 8x 20x Average
depth
38 Mb 63.34% 97.58% 81.68% 62.89% 64.41x
50 Mb 74.43% 95.24% 82.32% 65.37% 55.78x
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Genome wide SNP genotyping data on 159 samples was
utilized to perform a quality check and confirm sample
identity [28,29]. All but two samples passed quality con-
trol metrics. Therefore, we compared the single nucleotide
variant (SNV) calls between the whole exome sequencing
and SNP genotyping in 157 samples to confirm sample
identity and found an average concordance of 98.3%.
Genotyping and identity by descent filtering
Of the 164 samples selected for exome sequencing,
159 were also evaluated on one of four Illumina whole
genome genotyping arrays: the Human 1Mv1 Bead-
Chip (n = 129), the 1 M-DuoV3 BeadChip (n = 24), the
HumanOmniExpress-12 v1.0 BeadChip (n = 4), or the
HumanOmni2.5-4v1 BeadChip (n = 2). The 1 M and 1
M-Duo BeadChips were analyzed as previously described
[28,29]. Samples processed on the OmniExpress BeadChip
were prepared following Illumina’s Infinium HD Assay
Ultra protocol, while those processed on the Huma-
nOmni2.5 BeadChip followed Illumina’s Infinium HD
Assay Super protocol. All chips were processed with
automation on the Tecan (Männedorf, Switzerland) EVO-1
and BeadChips were scanned by either the Illumina
BeadArray Reader or iScan. Data was extracted by the
Genome Studio software from data files created by the
iScan (Illumina) and a GenCall cutoff score of 0.15 was
used. Samples on each of the four types of BeadChips
were required to have a genotyping call rate of 98% or
higher to pass quality control. Concordance between
the genotypes of the variants identified through exome
sequencing and genotyping was evaluated using the
PLINK program [30]. All but two samples passed quality
control metrics. Therefore, we compared the SNV calls
between the whole exome sequencing and SNP genotyp-
ing in 157 samples to confirm sample identity and found
an average concordance of 98.3%.
Genotyping information was further used to delineate
IBD regions within each extended family. Only the 100
individuals with a confirmed ASD diagnosis were used to
determine each family’s IBD regions. PLINK was employed
for linkage disequilibrium (LD) pruning using the CEPH
(Centre d'Etude du Polymorphisme Humain) CEU Hap-
Map data for all families except 7606, for which the
Yoruban (YRI) HapMap dataset was used [30]. The
indep-pairwise option was utilized with a window sizeof 50, a step of 5, and an r2 threshold of 0.5. Next, these
locations and their HapMap allele frequencies were ana-
lyzed in our dataset using the extended option in the
MERLIN program using the 164 samples that were exome
sequenced and 222 additional relatives [31]. To determine
the start and stop positions of IBD sharing regions within
each family, the MERLIN output was evaluated in a sliding
window of ten SNVs, defining IBD as sharing at each loca-
tion with a threshold >50%. Only regions shared across all
available ASD individuals within a family were used to de-
termine the IBD sharing segments.
To identify alterations inherited by all ASD individuals in
a family from a single ancestor, whole exome sequencing
data was restricted to IBD regions. Priority was also given
to novel variants and rare SNVs. We define rare SNVs as
those with a minor allele frequency (MAF), less than 5% in
each of the three HapMap populations (African, Asian, or
European), as well as in the 5,379 samples from the NHLBI
Exome Sequencing Project, Exome Variant Server (EVS,
version 5400) [32], and 308 HIHG control exomes. Novel
variants were defined as those absent from the EVS, the
1000 Genomes Project [33], and dbSNP 134 [34]. Variants
were evaluated for conservation with the Genomic Evolu-
tionary Rate Profiling (GERP) score [35] and alterations
measured for likelihood of having a damaging consequence
on protein function through the PolyPhen-2 [27] and SIFT
programs [28]. We also examined our results for overlap in
genes previously reported in the literature and publically
available databases (that is, SFARI Gene) to be associated
with ASDs and other neurological disorders including
ADHD, bipolar disorder, developmental delay, epilepsy,
intellectual disability, major depression, obsessive compul-
sive disorder, schizophrenia, speech disorders, and Tourette
syndrome [2,36,37].
Enrichment of ASD genes
To determine whether there was enrichment of ASD genes
in the IBD, damaging variants that were identified, results
were compared to a list of 1,075 genes that included known
and suspected ASD candidate genes [Additional file 1:
Table S3]. This list was compiled from the review by
Betancur [2], the ASD and candidate genes lists generated
by Pinto and colleagues [37], three autism exome de novo
papers [15-17], and the SFARI Gene database [36]. The
P value was calculated using a hypergeometric distribution.
Validation of variants
Of the 164 individuals from ASD extended families
included in this study, 100 samples were also run on the
Infinium HumanExome 12v1 BeadChip (Illumina). Exome
chips were prepared following the manufacturer’s Infi-
nium HD Assay Ultra protocol and automated using the
Tecan EVO-1, as described above. Samples were required
to have a genotyping call rate of 98% or higher to pass
Figure 2 Diagram of genes of high interest. The area of each
circle corresponds to the number of genes identified in one of four
categories: genes previously implicated as ASD candidates, non-ASD
genes that have been implicated in other neurodevelopmental and
neuropsychiatric disorders, genes found to have damaging variants
in more than one family, and genes that carry two damaging alter-
ations in the same family. ASD, autism spectrum disorder.
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the exome sequencing and genotyping with the PLINK
program [30]. Between the exome sequencing and exome
genotyping platforms, 446 changes were concordant, while
only one variant was found to be discordant. A subset of
variants was also validated by Sanger sequencing. Variants
present in multiple families were prioritized, as were
those occurring in genes with previous evidence impli-
cating them in neurodevelopmental and neuropsychi-
atric disorders. Primers were created using the Primer3
v0.4.0 program (http://fokker.wi.mit.edu/primer3/input.
htm) and the UCSC reference genome (GRCh37/hg19).
Sequencing reactions were performed with the Big Dye
Terminator v3.1, run on an Applied Biosystems 3730xl
DNA Analyzer (Life Technologies, Carlsbad, CA, USA),
and evaluated in the Sequencher v4.10.1 program (Gene
Codes Corporation, Ann Arbor, MI, USA). Fifty-seven
IBD changes were validated via Sanger sequencing, while
one position failed to validate. With a total of 503/505
SNVs (99.6%) being concordant in two independent
platforms, we determined that there is a relatively low
false positive rate of variant calling in the filtered exome
sequencing data.
Results and discussion
Identification and validation of rare and potentially
damaging variants
Whole exome sequencing was performed in 164 individuals
from 40 families to detect potentially causative variants
[Additional file 1: Table S1 and S2]. SNP genotyping data
on these 164 individuals and 222 relatives was used to
isolate genomic areas inherited from a common ancestor,
or IBD, and shared between ASD relatives (Figure 1).
Following variant calling of the exome data and rigorous
quality control (see Methods section), each family had
SNVs at approximately 90,000 unique locations. We tested
heterozygous, homozygous, and X-linked inheritance
models using the same scheme (Figure 1). To investigate
the first model, variants were filtered to include only IBD,
heterozygous alterations present in all affected individuals
within a family and predicted to be detrimental by either
altering amino acids or splicing patterns. Variants were
further parsed to include only those that were novel or
relatively rare (MAF, <5%) in HapMap populations, EVS
exomes, and 308 internally processed HIHG control
exomes. A total of 742 IBD, heterozygous alterations in
690 genes were identified across the 40 families. This
method was repeated with a homozygous model but no
alterations survived the filtering process. Sixteen of the
40 families conformed to a possible X-linked pattern of
inheritance and variants in three additional genes were
found [Additional file 1: Table S1]. Therefore, a total of
745 rare, predicted damaging, alterations in 693 genes
were identified. Three families did not demonstrate IBDco-segregation of any SNVs, while the remaining 37
families had at least two segregating SNVs. We then val-
idated 502 of the 745 IBD variants of interest by one of
two methods: Sanger sequencing or SNP genotyping
[Additional file 1: Table S4].
Genes identified with more than one variant
We identified 36 genes that had segregating SNVs in at
least two families (Figure 2, Additional file 1: Table S5). To
put these new findings in context, we examined the ASD
pedigrees for the presence of additional neurobehavioral
features in both affected individuals and obligate carriers of
the mutations of interest. While 32 of these genes have not
been previously linked to ASDs, one of them, SLIT3, has
been associated with another neuropsychiatric disorder
(Table 2). Duplications overlapping the SLIT3 gene were
previously found to be overrepresented in individuals with
major depressive disorder [38]. In our study, the two fam-
ilies carrying an alteration in SLIT3, 17342 and 18074, also
presented with a history of depression in three of the four
obligate carriers (all female); the fourth obligate carrier
was male and had no reported neuropsychiatric traits.
In addition, four ASD candidate genes were found with
alterations in more than one extended family: CEP290,
CSMD1, FAT1, and STXPB5. Alterations in CEP290 have
been connected to ASDs and intellectual disability and
were previously identified in patients diagnosed with a
Table 2 Damaging, validated variants in genes previously implicated in ASD or other disorders in multiple families
Gene Family Position
(Hg19)
dbSNP Nucleotide Amino acid HIHG control
chromosomes
Disorder References
CEP290 37425 chr12:88472996 rs61941020 C > T Arg1746Gln 3/610 ASD, ID Coppieters et al., 2010 [39]
37117 chr12:88508258 rs79705698 T > C Asp664Gly 15/612 ASD, ID Coppieters et al., 2010 [39]
CSMD1 37117 chr8:2965294 - G > C Pro2262Ala 2/614 ASD, SZ Havik et al., [40]
17122 chr8:3253832 - C > T Gly827Asp 0/604 ASD, SZ Havik et al., [40]
FAT1 37037 chr4:187518041 rs72716244 T > C Asp4218Gly 11/610 ASD, BD Blair et al., [43], Neale et al., [15]
17545 chr4:187549364 rs111886222 G > A Thr1585Met 5/614 ASD, BD Blair et al., [43], Neale et al., [15]
17545 chr4:187557908 rs113970444 C > T Arg1268Gln 5/608 ASD, BD Blair et al., [43], Neale et al., [15]
SLIT3 17342, 18074 chr5:168180047 rs34260167 C > T Ser629Asn 7/616 MD Glessner et al., [38]
STXBP5 37994 chr6:147635108 rs144099092 A > G Leu412Val 2/614 ASD Davis et al., [44]
7623 chr6:147636753 rs148830578 T > A Try502Cys 2/614 ASD Davis et al., [44]
ASD, autism spectrum disorder; BD, bipolar disorder; HIHG, Hussman Institute for Human Genomics; ID, intellectual disability; MD, major depression;
SZ, schizophrenia.
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Meckel-Gruber, and Senior-Løken syndromes (http://med-
gen.ugent.be/cep290base/) [39]. Along with being linked to
ASDs, CSMD1 has been associated with schizophrenia and
is a known target of mir-137, a microRNA that regulates
neuronal maturation and adult neurogenesis [40-43]. FAT1
is a candidate for both ASD and bipolar disorder and is
a member of the cadherin gene family [15,44]. While we
did not identify individuals with mutations in FAT1 who
presented with bipolar disorder, the two obligate carriers
(female) in family 17545 reported a history of major de-
pression. Lastly, a deletion across STXBP5 was previously
reported in a patient with autism, intellectual disabilities,
and seizures [45]. STXBP5 functions in neuronal guidance
and synaptic transmission [46]. In our first family identified
with a STXBP5 variant, 37994, we observed intellectual
disability in both of the ASD individuals as well as seizures
in the proband (1). In addition, the mother (1001) of the
proband was reported to have bipolar disorder. In the
second family carrying a mutation in STXBP5, 7623, we
observed seizures in one of the affected individuals (101)
as well as migraines in his mother (1007), an obligate
carrier. These results augment the growing evidence
supporting a genetic overlap between a wide variety of neu-
rodevelopmental and neuropsychiatric disorders [7-11].
Fourteen genes segregated two heterozygous and dam-
aging SNVs in cis within a single family; 12 of these genes
have no prior evidence of a connection to ASDs (Figure 2,
Additional file 1: Table S6). Two novel genes have been
identified in other neurodevelopmental and neuropsychi-
atric disorders: PRICKLE1 and OFCC1 (Table 3). Family
37232 carries two changes in PRICKLE1, a gene involved
in neurite outgrowth which has been linked to epilepsy
and neural tube defects [47-50]. Interestingly, the proband
of this family (1) was reported to have a history of sei-
zures. Independently, Paemka and colleagues implicatedPRICKLE1 as an ASD gene through extensive in vivo and
in vitro functional analysis [51], thereby demonstrating
the power of the extended family approach to identify
novel ASD candidates. Moreover, OFCC1, a gene linked
with Tourette syndrome [52], was found to have both a
missense and a nonsense alteration in family 7606, the
one family of African ancestry in this study. In this family,
we observed self-injurious behaviors in all three affected
individuals as well as seizures in one affected (2061). In
addition, two ASD genes were found to carry variants
in cis: ABHD14A and FAT1. Family 17351 carries two
changes in ABHD14A, a gene involved in cerebellar devel-
opment [53,54]. In this family, one affected individual
(105) was described as having intellectual disability and a
male obligate carrier (1000) was reported to have bipolar
disorder. Another ASD candidate gene, FAT1, has two
alterations in family 17545, as well as a distinct variant
detected in family 37037 [15,44]. As mentioned above,
family 17545 reported that both obligate carriers in the
family have a history of major depression.
Single alterations found in genes related to
neurological disorders
Three additional genes related to other neuropsychiatric
and neurodevelopmental disorders were each recognized to
carry a single IBD alteration: AP4M1 (intellectual disability
[55]), CLCN2 (epilepsy [56]), and WDR60 (intellectual dis-
ability and schizophrenia [57], Additional file 1: Table S7).
Moreover, an additional 38 known or suspected ASD genes
were identified with one variant, including AGAP1 [58],
CDH9 [28,59], DLGAP2 [60], FBXO40 [61], GRIN3B [13],
NRXN2 [62], and SYNE2 [14]. Following an X-linked pat-
tern of inheritance, hemizygous alterations were identified
and validated in SYN1, a gene which encodes a synaptic
vesicle phosphoprotein and has been previously connected
to both autism and epilepsy [63-65]. Both ASD individuals
Table 3 Families with multiple damaging, validated variants in the same, previously implicated gene
Gene Family Position
(Hg19)
dbSNP Nucleotide Amino acid HIHG control
chromosomes
Disorder References
ABHD14A 17351 chr3:52011912 rs17849626 G > A Arg32Gln 25/614 ASD Casey et al., [53]
chr3:52014897 rs61729088 C > G Arg227Gly 2/616 ASD Casey et al., [53]
FAT1 17545 chr4:187549364 rs111886222 G > A Thr1584Met 5/614 ASD, BD Blair et al., [43], Neale et al., [15]
chr4:187557908 rs113970444 C > T Arg1268Gln 5/608 ASD, BD Blair et al., [43], Neale et al., [15]
OFCC1 7606 chr6:9809860 - C > T Arg538Gln 0/602 TS Sundaram et al., [51]
chr6:9900660 rs148761621 C > A Glu204Stop 0/614 TS Sundaram et al., [51]
PRICKLE1 37232 chr12:42862463 rs61924369 C > T Glu185Lys 0/614 E Bassuk et al., [47], Tao et al., [49]
chr12:42864125 - C > G Val57Leu 0/614 E Bassuk et al., [47], Tao et al., [49]
ASD, autism spectrum disorder; BD, bipolar disorder; E, epilepsy; HIHG, Hussman Institute for Human Genomics; TS, Tourette syndrome.
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history of epilepsy. Interestingly, Paemka and colleagues
independently show that SYN1 co-immunoprecipitated
with PRICKLE1 in mouse brain and that the proteins
co-localized in Drosophila neurons [51], demonstrating
a conserved physical interaction between a newly identified
candidate gene, PRICKLE1, and an established ASD gene,
SYN1, and supporting the validity of our exome filtering
method. This provides additional evidence that investigat-
ing genes and pathways that interact with known ASD
candidates will likely prove a fruitful area for the identifi-
cation of ASD related genes.
Further potentially novel ASD candidates identified by
exome sequencing include genes with previous clinical
and molecular evidence supporting a neuronal function
such as CIC, GLUD2, NTSR2, RODG1, and SEZ6. CIC is a
genetic modifier of the neurodegenerative disorder spino-
cerebellar ataxia [66]. GLUD2 plays a role in postsynaptic
density formation in the cerebellum and modifies the age
of onset of Parkinson’s disease patients [67,68]. NTSR2 is
a G protein-coupled receptor for neurotensin that is widely
expressed throughout the brain [69]. RODG1 mutations
result in Kohlschütter-Tönz syndrome, a disorder that
presents with epilepsy and developmental delay, both
features found in children with autism [70]. Lastly, SEZ6
acts in dendritic arborization and has been associated with
seizures in a Chinese cohort [71,72]. This category of genes,
along with genes identified to carry alterations in more than
one family, may be the most fruitful groups of novel ASD
candidates for future investigations.
IBD filtering enriches for ASD candidate genes
In order to determine whether our filtering method
enriched for ASD specific variants, we generated a list
of 1,075 known and suspected ASD candidates from the
literature and the SFARI Gene database [2,15-17,36,37].
When this ASD candidate list was compared to the 693
genes carrying variants meeting the above filter criteria,
we found that 5.7% of the genes in the ASD list met
our criteria compared to only 3.4% of all genes capturedby the exome sequencing; thus, we were 1.65 times more
likely to find a variant in an ASD candidate gene than a
random gene captured by exome sequencing (P = 8.55 ×
10-5). We therefore concluded that there was a significant
enrichment of ASD candidate genes carrying damaging,
segregating variants, supporting our hypothesis that whole
exome sequencing of extended autism families is a reliable
approach to identify new autism genes.
Conclusions
Our results have identified several new genes that likely
play a role in ASD and provide additional support for the
role of other proposed ASD genes. These data reinforce
two emerging observations about ASDs. The first is the
extreme level of genetic heterogeneity, with no locus
contributing to more than 1% of ASD cases [2,73]. The
second is that there is significant overlap between the
genetic etiology of ASD and other neuropsychiatric and
neurodevelopmental disorders [7-11]. These data, taken
together with the increasing amount of functional data
available for many of these genes such as PRICKLE1
[51], highlight the enormous complexity of ASD and the
difficulties in resolving this enigma.
Additional file
Additional file 1: This file contains the seven tables listed below:
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